STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #65 by analyst upside · 2026-06-27
SNTI
Senti Biosciences Holdings, Inc.
Healthcare · Market Cap $34M · P/E 0x
ANALYST PRICE TARGET
+1092.7%
implied upside to consensus target
Current Price $1.09
Consensus Target $13.0
Bull Target $15.0
Bear Target $12.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
0
Sell
0
52-Week Low $0.77
52-Week High $2.88
YTD Return -0.9%
FUNDAMENTALS
Market Cap $34M
P/E Ratio (TTM) N/A
Forward P/E -1.1x
EPS (TTM) $-1.46
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.77
52-Week High $2.88
Current Price $1.09
Bear Target $12.0
Bull Target $15.0
● Now $1.09 ● Target $13.0
TRADING DATA
Avg Volume 201K
YTD Return -0.9%
Analyst Count 3
Consensus Buy
Upside to Target +1092.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Senti Biosciences Holdings, Inc. (SNTI) is currently trading at $1.09 with a Wall Street consensus price target of $13.0, implying potential upside of 1092.7% over the next 12 months. 3 analysts currently cover SNTI, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $12.0.

SNTI operates in the Healthcare sector with a market capitalisation of $34M. The stock is down 0.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.77 – $2.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SNTI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital — Reiterated
Buy → Buy 2026-05-15 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-03-30 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-12-09 33% win rate (6 calls)
Leerink Partners ● Initiated
Outperform 2025-11-21 29% win rate (7 calls)
HC Wainwright & Co. ● Initiated
Buy 2025-10-14 31% win rate (48 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-06-12 33% win rate (6 calls)
Laidlaw & Co. ● Initiated
Buy 2025-06-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →